Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

FDA Approves Ivosidenib as First-Line Treatment for AML with IDH1 Mutation

americanpharmaceuticalreviewMay 05, 2019

Tag: ivosidenib , FDA , AML

PharmaSources Customer Service